Sinovac Biotech LTD

1Globe Capital LLC, 1Globe Biomedical (Hong Kong) Company Limited, and Dr. Jiaqiang Li have increased their beneficial ownership in Sinovac Biotech Ltd. to 32.3% while actively engaged in multiple ongoing legal disputes concerning corporate control and share validity.

SAIF Partners IV L.P. and YZ Healthcare L.P. have amended and restated their investment agreement concerning the sale of Sinovac Biotech Ltd. common shares, extending key option periods and clarifying terms.

Sinovac Biotech Ltd. has announced the formation of a new Board of Directors, with significant shareholder Weidong Yin accepting an appointment to the board and expressing intent to engage in corporate governance discussions to enhance shareholder value.

Advantech Capital and allied shareholders successfully elected new directors to Sinovac Biotech's board after a contested Special Meeting, overcoming an interim injunction.

SAIF Partners IV L.P. and its affiliates have filed an amended Schedule 13D for Sinovac Biotech Ltd., disclosing a 15% beneficial ownership stake, the formation of a new board of directors, and ongoing discussions with other shareholders to enhance corporate governance and shareholder value.

A U.S. District Court has issued a preliminary injunction against 1Globe Capital and its owner, Jiaqiang Li, for making materially misleading statements regarding Sinovac Biotech Ltd., coinciding with the election of a new board of directors supported by Vivo Capital.